Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-IGE therapy in asthma].

Nadia Mehiri Ben Rhouma1, Majed Béji, Béchir Louzir

  • 1Service Pneumo-Allergologie, Hôpital La Rabta Tunis.

La Tunisie Medicale
|March 14, 2003
PubMed
Summary

Nonanaphylactogenic anti-human immunoglobulin E (IgE) antibodies effectively treat asthma by reducing IgE levels and allergic responses. This therapy shows promise for managing atopic diseases with minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic approach to endobronchial metastases from extra-thoracic neoplasms: A report of three cases and brief review of literature.

La Tunisie medicale·2025
Same author

Laboratory findings predictive of critical illness in hospitalized COVID-19 patients in Tunisia.

F1000Research·2024
Same author

A rare coexistence of sarcoidosis with overlap syndrome and sarcoidosis with primary biliary cholangitis and Sjogren's syndrome: Two distinct case reports.

Heliyon·2024
Same author

Pulmonary aspergilloma with prominent oxalate deposition.

Clinical case reports·2022
Same author

Anxiety and depression in Tunisian patients with COPD.

La Tunisie medicale·2022
Same author

[Paraneoplastic limbic encephalitis complicating pulmonary adenocarcinoma: a case report].

The Pan African medical journal·2021

Area of Science:

  • Immunology
  • Allergy Research
  • Pharmacology

Context:

  • Immunoglobulin E (IgE) is a key marker in allergic diseases and asthma.
  • Therapeutic strategies focus on regulating IgE production.
  • Nonanaphylactogenic anti-IgE antibodies are emerging as a treatment option.

Purpose:

  • To evaluate the efficacy and safety of anti-IgE antibody therapy in asthmatic patients.
  • To assess the impact of anti-IgE antibodies on plasma IgE levels and allergic responses.
  • To determine the potential of anti-IgE therapy as a treatment for asthma.

Summary:

  • Administration of monoclonal anti-IgE antibodies in asthmatic subjects led to reduced plasma IgE levels.
  • These antibodies decreased early and late phase allergic responses post-allergen provocation.
  • Patients experienced improved asthma symptoms and reduced need for rescue medication.

Impact:

  • Anti-IgE therapy demonstrates clinical effectiveness in managing asthma.
  • The treatment shows a favorable safety profile with no serious side effects reported.
  • This supports anti-IgE therapy as a viable treatment option for allergic asthma.

Related Experiment Videos